Zyversa Therapeutics, Inc. (ZVSA) Stock Price & Analysis

Zyversa Therapeutics, Inc. (ZVSA) rose 4.04% to USD 0.1 as of September 8, 2026 at 06:57 UTC, according to Nexqual real-time market data.

ZVSA last closed at USD 0.1; the session ranged USD 0.1–0.1 on volume of 2,400 shares. Market capitalization is —, with a 52-week range of USD 0.08–0.3 (PNK). Source: Nexqual, September 8, 2026 at 06:57 UTC.

Key Statistics (as of September 8, 2026 at 06:57 UTC)

Technical Analysis (ZVSA)

Nexqual's technical model rates ZVSA "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:57 UTC.

From Zyversa Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We intend to use these marks in connection with our pharmaceutical product candidates currently in development as added levels of intellectual property protection for our proprietary technologies.   Regulatory Matters   In the United States, the FDA regulates drug products, biological products, and medical devices under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the Public Health Service Act ("PHSA"), and other federal laws and regulations.
• VAR 200, IC 100, and any other product candidates that we may seek to develop or acquire in the future must be approved by the FDA through the New Drug Application ("NDA"), Biologic Licensing Application ("BLA") or other applicable approval process before they may be legally marketed in the United States.     The clinical stages of development can generally be divided into three sequential phases that may overlap: Phase 1, Phase 2 and Phase 3 clinical trials.
• Such is often the case when the safety and efficacy of an API is considered to be well understood by the FDA.
• Regulatory authorities, including the FDA, an IRB, a data safety monitoring board or the Sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk or that the clinical trial is not being conducted in accordance with FDA requirements.   During the development of a new drug or biologic, sponsors are given opportunities to meet with the FDA at certain points.

Partnerships

• The Restatement provides that, with respect to the Milestone Payments, L&F Research waives its right to terminate the L&F License Agreement and exercise any other remedies thereunder, until (a) March 31, 2023, as to $1,000,000 of such Milestone Payments ("Waiver A"), and (b) January 31, 2024, as to $500,000 of such Milestone Payments ("Waiver B").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:57 UTC. This page is informational and not investment advice.